Exact Mass: 696.3543146000001

Thalicarpin

C41H48N2O8 (696.3410488000001)

C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent C1907 - Drug, Natural Product

Olitorin

C35H52O14 (696.3356891999999)

Isolated from Corchorus olitorius (Jews mallow). Olitorin is found in tea, herbs and spices, and green vegetables. Olitorin is found in green vegetables. Olitorin is isolated from Corchorus olitorius (Jews mallow D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

Cenicriviroc

C41H52N4O4S (696.3709072)

Fluorescein dilaurate

C44H56O7 (696.4025826)

D004396 - Coloring Agents > D005456 - Fluorescent Dyes > D005452 - Fluoresceins D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents

Periplocin

C36H56O13 (696.3720726)

PA(12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C37H61O10P (696.4002135999999)

PA(12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/12:0)

C37H61O10P (696.4002135999999)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/12:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C37H61O10P (696.4002135999999)

PA(12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/12:0)

C37H61O10P (696.4002135999999)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/12:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(14:1(9Z)/PGJ2)

C37H61O10P (696.4002135999999)

PA(14:1(9Z)/PGJ2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/PGJ2), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGJ2/14:1(9Z))

C37H61O10P (696.4002135999999)

PA(PGJ2/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGJ2/14:1(9Z)), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C37H61O10P (696.4002135999999)

PA(i-12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-12:0)

C37H61O10P (696.4002135999999)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-12:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C37H61O10P (696.4002135999999)

PA(i-12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-12:0)

C37H61O10P (696.4002135999999)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-12:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Periplocin

C36H56O13 (696.3720726)

Origin: Plant; SubCategory_DNP: Triterpenoids Periplocin is a natural product found in Periploca sepium, Periploca forrestii, and other organisms with data available. Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase[1][2]. Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase[1][2].

PERIPLOGENIN 3-O-BETA-GLUCOPYRANOSYL-(1-4)-BETA-SARMENTOPYRANOSIDE

C36H56O13 (696.3720726)

Periplogenin 3-[O-|A-glucopyranosyl-(1 inverted exclamation marku4)-|A-sarmentopyranoside] is a natural product found in Periploca sepium with data available.

Bearline

C37H48N2O11 (696.3257938)

SCHEMBL869252

C36H56O13 (696.3720726)

Mollamide B

C36H52N6O6S (696.3668852000001)

Clerocidin

C40H56O10 (696.3873276)

2,4-Bis[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxo-1-cyclohexenyl)-2-methylpropyl]-6-hexanoylbenzene-1,3,5-triol

C40H56O10 (696.3873276)

Trilocularoside A

C36H56O13 (696.3720726)

Cucurbitacin G 2-O-beta-D-glucopyranoside

C36H56O13 (696.3720726)

Hexamollamide

C36H52N6O6S (696.3668852000001)

Pipeloside A

C31H52O17 (696.3204342)

Bismurrayafoline C

C46H52N2O4 (696.3926872000001)

Boivinide E

C35H52O14 (696.3356891999999)

Potanidine B

C37H48N2O11 (696.3257938)

ST023286

C41H48N2O8 (696.3410488000001)

rel-(2R,3S,6R,7S,8S,9S,13R,14S,15S)-(4E,11E)-8,14,15-triacetoxy-3-(benzoyloxy)-6,9-epoxy-9-hydroxy-7-(tigloyloxy)jatropha-4,11-diene

C38H48O12 (696.3145608)

C35H52O14

C35H52O14 (696.3356891999999)

adociasulfate 8

C36H56O9S2 (696.3365566000001)

5-Demethoxy,8-methoxy-2,2,3,3-Tetrahydro-3,3,6,7,7,8-hexamethoxy-4-(4-methoxyphenyl)-4-phenyl-5,6-bi-1H-phenalene,

C45H44O7 (696.3086874)

2alpha,3beta,6beta,19alpha,24-pentahydroxy-11-oxo-olean-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester

C36H56O13 (696.3720726)

4-dehydrosarmentogenin rhamnoglucoside

C35H52O14 (696.3356891999999)

dircin

C39H52O11 (696.3509442000001)

Erysimoside

C35H52O14 (696.3356891999999)

A cardenolide glycoside that consists of strophanthidin having a beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl moiety attached at position 3. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

17-Thevebioside

C36H56O13 (696.3720726)

10alpha,13alpha,16alpha-trihydroxy-9alpha-methyl-15-oxo-20-nor-kauran-19-oic acid gamma-lactone-17-yl-16alpha,17-dihydroxy-15-oxo-ent-kaur-19-oate

C40H56O10 (696.3873276)

Odoroside F

C36H56O13 (696.3720726)

3,5-Bis[[2,6-dihydroxy-4-methoxy-3-methyl-5-(2-methylpropanoyl)phenyl]methyl]-2-hydroxy-3,5-dimethyl-1-(2-methylpropanoyl)-1-cyclohexene-4,6-dione

C38H48O12 (696.3145608)

alloxysmalorin

C35H52O14 (696.3356891999999)

Odorobiosid G

C36H56O13 (696.3720726)

oxystelmine

C36H56O13 (696.3720726)

desotamide

C35H52N8O7 (696.3958762)

C36H56O13

C36H56O13 (696.3720726)

16,17-dihydroneridienone 3-O-beta-D-glucopyranosyl-(1 -> 6)-O-beta-D-galactopyranoside

C35H52O14 (696.3356891999999)

Trachelosperoside C1

C36H56O13 (696.3720726)

Xysmalorin

C35H52O14 (696.3356891999999)

cheiranthoside II

C35H52O14 (696.3356891999999)

C41H48N2O8

C41H48N2O8 (696.3410488000001)

glucosyl divaricoside

C36H56O13 (696.3720726)

Elatine

C37H48N2O11 (696.3257938)

glucocheiranthoside

C35H52O14 (696.3356891999999)

C45H57ClO4

C45H57ClO4 (696.3945151999999)

Stromemycin

C38H48O12 (696.3145608)

C38H48O12

C38H48O12 (696.3145608)

C31H52O17

C31H52O17 (696.3204342)

hibispeptin B

C36H52N6O8 (696.3846432)

19-(formyl<*>carboxy)erysimin 4-O-alpha-L-rhamnopyranoside|3-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-digitoxopyranosyl cheiranthidin|cheiranthoside X|cheiranthoside XI

C35H52O14 (696.3356891999999)

2alpha,3beta,19alpha,23,24-pentahydroxy-11-oxo-olean-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester

C36H56O13 (696.3720726)

2,2,3,3-Tetrahydro-3,3,6,7,7,8-hexamethoxy-4-(4-methoxyphenyl)-4-phenyl-5,6-bi[1H-phenalene]

C45H44O7 (696.3086874)

3beta-(O4(?)-beta-D-Glucopyranosyl-beta-D-glucopyranosyloxy)-14-hydroxy-14beta-carda-5,20(22)-dienolid|3beta-(O4(?)-beta-D-glucopyranosyl-beta-D-glucopyranosyloxy)-14-hydroxy-14beta-carda-5,20(22)-dienolide

C35H52O14 (696.3356891999999)

16-hydroxyalbatrellin

C44H56O7 (696.4025826)

cannogenol-beta-D-glucosyl-beta-D-cymaroside

C36H56O13 (696.3720726)

9-{6-[(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-2,3-dimethoxyphenoxy}-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline

C41H48N2O8 (696.3410488000001)

relative retention time with respect to 9-anthracene Carboxylic Acid is 0.738 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.733

C35H52O14_Carda-5,20(22)-dienolide, 3-[(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-14-hydroxy-, (3beta)

C35H52O14 (696.3356891999999)

C35H52O14_Carda-5,17-dienolide, 3-[(3-O-hexopyranosylhexopyranosyl)oxy]-14-hydroxy-, (17E)

C35H52O14 (696.3356891999999)

Thaliblastine

C41H48N2O8 (696.3410488000001)

Formula(Parent): C41H48N2O8; Origin: Plant; Bottle Name:Thalicarpine hydrochloride; PRIME Parent Name:Thalicarpine; PRIME in-house No.:V0344; SubCategory_DNP: Isoquinoline alkaloids, Benzylisoquinoline alkaloids Origin: Plant; Formula(Parent): C41H48N2O8; Bottle Name:Thalicarpine hydrochloride; PRIME Parent Name:Thalicarpine; PRIME in-house No.:V0344; SubCategory_DNP: Isoquinoline alkaloids, Benzylisoquinoline alkaloids

Olitoriside

C35H52O14 (696.3356891999999)

Origin: Plant, Cardanolides

Odorobioside G

C36H56O13 (696.3720726)

Olitorin

C35H52O14 (696.3356891999999)

D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

OOV-PI

C32H57O14P (696.3485751999999)

Fucoxanthinol 3-sulphate

C40H56O8S (696.3695696000001)

Bastaxanthol b diacetate

C44H56O7 (696.4025826)

ir-768 perchlorate

C42H49ClN2O5 (696.3329814)

2-benzofuran-1,3-dione,2-hydroxyethyl prop-2-enoate,methyl 2-methylprop-2-enoate,oxiran-2-ylmethyl 7,7-dimethyloctanoate,styrene

C39H52O11 (696.3509442000001)

benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid,2,2,4-trimethylpentane-1,3-diol

C33H60O15 (696.393201)

N,N-Bis(11-hydroxyundecanyl)bipyridinium diperchlorate (Viologen)

C32H54Cl2N2O10 (696.3155324)

Thevebioside

C36H56O13 (696.3720726)

Cenicriviroc

C41H52N4O4S (696.3709072)

COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist D065100 - CCR5 Receptor Antagonists Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

NY IV34 1

C41H48N2O8 (696.3410488000001)

C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent C1907 - Drug, Natural Product

PA(14:1(9Z)/PGJ2)

C37H61O10P (696.4002135999999)

PA(PGJ2/14:1(9Z))

C37H61O10P (696.4002135999999)

PA(12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C37H61O10P (696.4002135999999)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/12:0)

C37H61O10P (696.4002135999999)

PA(12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C37H61O10P (696.4002135999999)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/12:0)

C37H61O10P (696.4002135999999)

PA(i-12:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C37H61O10P (696.4002135999999)

PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-12:0)

C37H61O10P (696.4002135999999)

PA(i-12:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C37H61O10P (696.4002135999999)

PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-12:0)

C37H61O10P (696.4002135999999)

digitoxigenin 3-O-[beta-D-glucosyl-(1->4)-alpha-L-acofrioside]

C36H56O13 (696.3720726)

5-O-Methyl-26-(tigloyloxy)antibiotic VM-44866

C40H56O10 (696.3873276)

1-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C41H52N4O6 (696.3886652000001)

1-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C41H52N4O6 (696.3886652000001)

(8xi,9xi,14xi,17xi)-3-{[(4xi)-2,6-dideoxy-4-O-(D-glucopyranosyl)-beta-D-erythro-hexopyranosyl]oxy}-5,14-dihydroxy-19-oxocard-20(22)-enolide

C35H52O14 (696.3356891999999)

[2-Nonanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] nonanoate

C33H60O15 (696.393201)

(8xi,9xi,14xi,17xi)-3-{[(4xi)-2,6-dideoxy-4-O-(D-glucopyranosyl)-3-O-methyl-beta-D-erythro-hexopyranosyl]oxy}-5,14-dihydroxycard-20(22)-enolide

C36H56O13 (696.3720726)

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

C33H60O15 (696.393201)

[1-Octanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

C33H60O15 (696.393201)

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

C33H60O15 (696.393201)

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] hexadecanoate

C33H60O15 (696.393201)

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tetradecanoate

C33H60O15 (696.393201)

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentadecanoate

C33H60O15 (696.393201)

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

C33H60O15 (696.393201)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C37H61O10P (696.4002135999999)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C37H61O10P (696.4002135999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-henicos-11-enoate

C33H61O13P (696.3849585999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-nonadec-9-enoate

C33H61O13P (696.3849585999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C37H61O10P (696.4002135999999)

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-icos-11-enoate

C33H61O13P (696.3849585999999)

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate

C33H61O13P (696.3849585999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

C33H61O13P (696.3849585999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] (Z)-pentadec-9-enoate

C33H61O13P (696.3849585999999)

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate

C33H61O13P (696.3849585999999)

[1-decanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate

C33H61O13P (696.3849585999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (Z)-tridec-9-enoate

C33H61O13P (696.3849585999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C37H61O10P (696.4002135999999)

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-docos-13-enoate

C33H61O13P (696.3849585999999)

[(2S,3S,6S)-6-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H52O12S (696.3179312)

[(2R)-2-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (E)-tetradec-9-enoate

C33H61O13P (696.3849585999999)

[(2R)-1-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (E)-tetradec-9-enoate

C33H61O13P (696.3849585999999)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C37H61O10P (696.4002135999999)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C37H61O10P (696.4002135999999)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H61O10P (696.4002135999999)

Thalicarpine

C41H48N2O8 (696.3410488000001)

C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent C1907 - Drug, Natural Product

phosphatidylserine 30:5(1-)

C36H59NO10P (696.3876384)

A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 30 carbons in total and 5 double bonds.

SMGDG O-24:2;O

C33H60O13S (696.375443)

SQDG 24:1;O

C33H60O13S (696.375443)

SQDG 26:7

C35H52O12S (696.3179312)

SQMG 27:7

C36H56O11S (696.3543146000001)

PA 14:0/20:6;O2

C37H61O10P (696.4002135999999)

PA 14:1/20:5;O2

C37H61O10P (696.4002135999999)

PA 22:4/11:3;O3

C36H57O11P (696.3638301999999)

PA 22:4/12:2;O2

C37H61O10P (696.4002135999999)

PA 33:7;O3

C36H57O11P (696.3638301999999)

PA 34:6;O2

C37H61O10P (696.4002135999999)

HBMP 30:6

C36H57O11P (696.3638301999999)

PG 18:4/12:3;O

C36H57O11P (696.3638301999999)

PG 20:0/7:2;O3

C33H61O13P (696.3849585999999)

PG 20:4/9:4;O2

C35H53O12P (696.3274468)

PG 22:4/8:3;O

C36H57O11P (696.3638301999999)

PG 22:5/7:3;O2

C35H53O12P (696.3274468)

PG 22:6/7:2;O2

C35H53O12P (696.3274468)

PG 22:6/8:1;O

C36H57O11P (696.3638301999999)

PG 27:2;O3

C33H61O13P (696.3849585999999)

PG 29:8;O2

C35H53O12P (696.3274468)

PG 30:7;O

C36H57O11P (696.3638301999999)

PI O-16:0/7:3;O2

C32H57O14P (696.3485751999999)

PI O-18:0/6:2;O

C33H61O13P (696.3849585999999)

PI O-23:3;O2

C32H57O14P (696.3485751999999)

PI O-24:2;O

C33H61O13P (696.3849585999999)

PI P-16:0/7:2;O2

C32H57O14P (696.3485751999999)

PI P-16:0/8:1;O

C33H61O13P (696.3849585999999)

PI P-18:1/5:1;O2

C32H57O14P (696.3485751999999)

PI P-20:0/4:1;O

C33H61O13P (696.3849585999999)

PI 14:0/8:3;O2

C31H53O15P (696.3121917999999)

PI 14:1/8:2;O2

C31H53O15P (696.3121917999999)

PI 14:1/9:1;O

C32H57O14P (696.3485751999999)

PI 18:1/5:1;O

C32H57O14P (696.3485751999999)

PI 18:2/4:1;O2

C31H53O15P (696.3121917999999)

PI 22:3;O2

C31H53O15P (696.3121917999999)

PI 10:0_14:1

C33H61O13P (696.3849585999999)

PI 20:0/4:1

C33H61O13P (696.3849585999999)

PI 20:1/4:0

C33H61O13P (696.3849585999999)

PI 22:1/2:0

C33H61O13P (696.3849585999999)

PI 24:1

C33H61O13P (696.3849585999999)

ST 29:4;O8;GlcA

C35H52O14 (696.3356891999999)

(1r,2e,4r,5s,7s,8r,9s,10e,13s,14r,15s)-7,8,14-tris(acetyloxy)-13-hydroxy-1,5,9,12,12-pentamethyl-15-{[(2e)-2-methylbut-2-enoyl]oxy}-16-oxatricyclo[11.2.1.0³,⁷]hexadeca-2,10-dien-4-yl benzoate

C38H48O12 (696.3145608)

7-[(6-{[(4,6-dihydroxy-2-methyloxan-3-yl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde

C35H52O14 (696.3356891999999)

4-{3-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]butyl}-3,5,5-trimethylcyclohex-2-en-1-one

C31H52O17 (696.3204342)

7,8,14-tris(acetyloxy)-13-hydroxy-1,5,9,12,12-pentamethyl-15-[(2-methylbut-2-enoyl)oxy]-16-oxatricyclo[11.2.1.0³,⁷]hexadeca-2,10-dien-4-yl benzoate

C38H48O12 (696.3145608)

8,8'-bis[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,3'-dimethyl-9h,9'h-[2,2'-bicarbazole]-1,1',7,7'-tetrol

C46H52N2O4 (696.3926872000001)

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-6-(9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-3-methylcyclohexa-2,5-diene-1,4-dione

C44H56O7 (696.4025826)

{4,8,9-trihydroxy-6,16,18-trimethoxy-11-propyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)benzoate

C38H52N2O10 (696.3621772)

(1r,2r,3as,3bs,8s,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,5r)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H56O13 (696.3720726)

(2s)-n-[(4s,10s,13s,16s)-3-ethyl-11,14,17,24-tetrahydroxy-13,16-bis(2-methylpropyl)-5,20-dioxo-6,12,15,18-tetraazatricyclo[19.3.1.0⁶,¹⁰]pentacosa-1(25),11,14,17,21,23-hexaen-4-yl]-5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboximidic acid

C36H52N6O8 (696.3846432)

(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-hydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carboxylic acid

C35H52O14 (696.3356891999999)

(4r)-4-[(3s)-3-{[(2r,3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-3,5,5-trimethylcyclohex-2-en-1-one

C31H52O17 (696.3204342)

4-[(1r,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C35H52O14 (696.3356891999999)

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-6-[(2e,6e,9r)-9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-3-methylcyclohexa-2,5-diene-1,4-dione

C44H56O7 (696.4025826)

3a-hydroxy-7-[(4-hydroxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carboxylic acid

C35H52O14 (696.3356891999999)

4,7-dihydroxy-1-(5-methyl-6-phenylhexyl)-6-[(6-methyl-9-phenylnon-4-enoyl)oxy]-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid

C38H48O12 (696.3145608)

(2r,3r,4r,4ar,6ar,6bs,8as,11s,12s,12as,14ar,14br)-2,3,12-trihydroxy-11-(hydroxymethyl)-4,6a,6b,12,14b-pentamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C36H56O13 (696.3720726)

(2s,5s,8s,14s,17s,20s)-14-benzyl-4,7,16,19-tetrahydroxy-2,5-diisopropyl-17-[(1r)-1-[(2-methylbut-3-en-2-yl)oxy]ethyl]-22-thia-3,6,12,15,18,23-hexaazatricyclo[18.2.1.0⁸,¹²]tricosa-1(23),3,6,15,18-pentaen-13-one

C36H52N6O6S (696.3668852000001)

(1r,2e,4s,5s,7r,8s,9r,10e,13s,14s,15r)-7,8,14-tris(acetyloxy)-13-hydroxy-1,5,9,12,12-pentamethyl-15-{[(2e)-2-methylbut-2-enoyl]oxy}-16-oxatricyclo[11.2.1.0³,⁷]hexadeca-2,10-dien-4-yl benzoate

C38H48O12 (696.3145608)

4-{7-[(6-{[(4,6-dihydroxy-2-methyloxan-3-yl)oxy]methyl}-3,5-dihydroxy-4-methoxyoxan-2-yl)oxy]-3a,5a-dihydroxy-9a,11a-dimethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

C36H56O13 (696.3720726)